RCS - Hutchmed China Ltd - Save the Date: HUTCHMED to Present R&D Updates

HUTCHMED (China)Announcement

24/06/2024 10:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240624:nRSX5827Ta&default-theme=true

RNS Number : 5827T  Hutchmed (China) Limited  24 June 2024

Press Release

 

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

 

- HUTCHMED will host in-person presentation and online webinar on Tuesday,
July 9 -

 

Hong Kong, Shanghai & Florham Park, NJ - Monday, June 24, 2024: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) ") (Nasdaq/AIM:HCM;
HKEX:13) today announces that it will host a R&D update in Shanghai,
China, and via webcast on Tuesday, July 9, 2024.

 

During the event, the senior management team will share insights into the
Company's R&D strategy and vision. Additionally, the team will provide
updates on certain programs within HUTCHMED's extensive and innovative
pipeline. This will include updates on the Phase III ESLIM‑01 and Phase
II/III ESLIM‑02 studies of our Syk inhibitor sovleplenib in immune
thrombocytopenia ("ITP") and warm antibody autoimmune hemolytic anemia,
("wAIHA") respectively; the surufatinib Phase II/III study for metastatic
pancreatic ductal adenocarcinoma ("PDAC"); and the Phase III RAPHAEL study of
our IDH1/2 inhibitor HMPL-306 in acute myeloid leukemia ("AML").

 

The in-person event will take place from 3:00 p.m. to 5:00 p.m. HKT in Chinese
(Putonghua) in Shanghai. A live webcast will be held simultaneously.
Attendance for the in-person event is by invitation only.

 

An English language webcast will take place from 8:30 p.m. HKT / 8:30 a.m. EDT
/ 1:30 p.m. BST on Tuesday, July 9, for approximately two hours.

 

Both webcasts will be live and can be accessed via www.hutch-med.com/event
(https://www.hutch-med.com/event/) . Investors interested in listening to a
webcast should log on before the start time to download any software required.
A replay of the event will be available shortly thereafter for approximately
90 days.

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has approximately
5,000 personnel across all its companies, at the center of which is a team of
about 1,800 in oncology/immunology. Since inception it has focused on bringing
cancer drug candidates from in-house discovery to patients around the world,
with its first three oncology drugs marketed in China, the first of which is
also marketed in the U.S. For more information, please visit:
www.hutch-med.com (https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements involve risks and uncertainties.
Existing and prospective investors are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date hereof.
For further discussion of these and other risks, see HUTCHMED's filings with
the U.S. Securities and Exchange Commission, The Stock Exchange of Hong Kong
Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the
information contained in this press release, whether as a result of new
information, future events or circumstances or otherwise.

 

CONTACTS
 Investor Enquiries                                                   +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 Ben Atwell / Alex Shaw, FTI Consulting                               +44 20 3727 1030 / +44 7771 913 902 (Mobile) /
                                                                      +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
                                                                      (mailto:HUTCHMED@fticonsulting.com)
 Zhou Yi, Brunswick                                                   +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                                      (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley / Rupert Dearden, Panmure Gordon    +44 (20) 7886 2500

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAVZLBLZQLXBBD